Rheumatoid Arthritis: Fujibayashi T

von Bültzingslöwen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, Wray D, Brennan MT, Carrozzo M, Gandera B, Fujibayashi T, Navazesh M, Rhodus NL, Schiødt M. · Department of Oral Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden. <> · Oral Surg Oral Med Oral Pathol Oral Radiol Endod. · Pubmed #17379156 No free full text.

Abstract: OBJECTIVES: The objective of this study was to identify systemic diseases associated with hyposalivation and xerostomia and develop evidence-based management recommendations for hyposalivation/xerostomia. STUDY DESIGN: Literature searches covered the English language medical literature from 1966 to 2005. An evidence-based review process was applied to management studies published from 2002 to 2005. RESULTS: Several systemic diseases were identified. From studies published 2002 to 2005, 15 were identified as high-quality studies and were used to support management recommendations: pilocarpine and cevimeline are recommended for treating hyposalivation and xerostomia in primary and secondary Sjögren's syndrome (SS). IFN-alpha lozenges may enhance saliva flow in primary SS patients. Anti-TNF-alpha agents, such as infliximab or etanercept, are not recommended to treat hyposalivation in SS. Dehydroepiandrosterone is not recommended to relieve hyposalivation or xerostomia in primary SS. There was not enough evidence to support any recommendations for the use of local stimulants, lubricants, and protectants for hyposalivation/xerostomia. However, professional judgment and patient preferences may support the use of a specific product for an individual patient. CONCLUSIONS: These evidence-based management recommendations should guide the clinician's management decisions for patients with salivary dysfunction related to systemic disease. Future treatment strategies may include new formulations of existing drugs, e.g., local application of pilocarpine. Recent discoveries on gene expression and a better understanding of the etiopathogenesis of SS may open new treatment options in the future.

Tsuboi S, Tamura Y, Fujibayashi T, Iwasada S, Miyake N. · Deparment of Rheumatology, Shizuoka Kousei Hospital, 23 Kitabanncho, Shizuoka, 420-8623, Japan, · Mod Rheumatol. · Pubmed #17028811 No free full text.

Abstract: We gave preoperative blood transfusions to 37 patients with rheumatoid arthritis (RA) and 35 patients with osteoarthritis (OA), including some whose baseline hemoglobin level was less than 10 g/dl. Transfusion packs can preserve whole blood containing citrate phosphate dextrose (CPD) for 3 weeks. The baseline hemoglobin level of RA cases was 10.4 g/dl (range 8.4-13.1 g/dl), and that of OA cases was 11.9 g/dl (range 10.4-15.0 g/dl). By collecting 200-400 g every week before the operation, the total was 800-1200 g. Erythropoietin was given to patients intramuscularly when their hemoglobin was less than 13 g/dl after blood had been collected. Hemagglutination, with diameters of more than 1 cm, made filter occlusions in 11 RA cases (30%) and one OA case (3%) (P << 0.0031) after retransfusion. There were no differences between hemagglutination patients (agglutination group) and nonhemagglutination patients (nonagglutination group) regarding baseline C-reactive protein (CRP), white blood cells, platelets, or fibrinogen. We could not predict the formation of macrohemagglutination in the packs collected during the clinical course. In RA cases, allogenic transfusions were performed for four cases (36%) in the agglutination group and for one case (12%) in the nonagglutination group. Preoperative transfusion for the RA patients showed hemagglutination in some cases, and highlighted the need for modifications to reduce these hemagglutinations.

Gotoh S, Watanabe Y, Fujibayashi T. · Department of Oral and Maxillofacial Surgery, Dokkyo University School of Medicine. Currently Haneishi Dental Clinic, Utsunomiya, Japan. · Oral Surg Oral Med Oral Pathol Oral Radiol Endod. · Pubmed #15716835 No free full text.

Abstract: OBJECTIVE: The purposes were to compare the practice effect of stimulated whole saliva collection (SWSC) with unstimulated whole saliva collection (UWSC), and to investigate the validity of the tests as a criterion in the diagnosis of Sjogren's syndrome (SS), allowing for the practice effect. STUDY DESIGN: SWSC (n = 34) or UWSC (n = 27) was performed 3 times on healthy volunteers to investigate practice effects; then the differences among the 3 measurements were analyzed. For evaluating the validity of the tests, UWSC and SWSC were performed alternately on 28 SS patients and 34 control subjects, all of whom had had a practice SWSC before the actual test; then the sensitivity and specificity of both tests as a criterion in the diagnosis of SS were calculated. RESULTS: A practice effect was observed for SWSC, but not for UWSC. When an orientation measurement was performed before the actual SWSC, there was no statistically significant difference between the accuracy of SWSC and UWSC as a criterion in the diagnosis of SS. CONCLUSION: If an orientation measurement is performed before the actual measurement, SWSC can be as valid a test for sialometric evaluation in the diagnosis of SS as UWSC.

Fujibayashi T, Tamura Y, Tsuboi S, Miyake N, Saitoh S. · Department of Orthopaedic Surgery and Rheumatology, Shizuoka Kousei Hospital, Shizuoka-city. · Ryumachi. · Pubmed #11296452 No free full text.

Abstract: OBJECTIVE: We evaluated cerebrovascular events (cerebral infarction or cerebral bleeding) in patients with rheumatoid arthritis (RA). METHODS: Prognosis and the causes of death among 1100 RA patients from 1995 to 1999, were analyzed. 34 RA patients were complicated by cerebrovascular events. About them, hemoglobin, platelet, C-reactive protein, rheumatoid factor, total cholesterol, triglyceride, duration of disease, functional class, and dose of steroids per day were measured. RESULT: Among 1100 patients with RA, 90 died at the age of 70.2. Of these patients, 24 (26.7%) died of cerebrovascular events, 19 (21.1%) of heart failure, 16 (17.8%) of infectious diseases, 10 (11.1%) of malignant tumors, and 9 (10%) of renal failure. When RA patients who died of cerebrovascular events were compared with those who died of other causes, the dose of steroid was significantly lower and the age was higher in RA patients who died of cerebrovascular events. However, there were no significant differences in total cholesterol and triglyceride levels between the two groups. Although the major cause of death in RA patients was reported to be complication by cardiovascular diseases, infectious diseases, or renal failure, the frequency of deaths was higher in elderly RA patients complicated by cerebrovascular events. When the frequency of complication by cerebrovascular events was investigated in all RA patients including those who survived, 24 died and 10 survived. The frequency of complication by cerebral infarction was higher than that of complication by cerebral bleeding in RA patients who died of cerebral events. CONCLUSION: RA patients can live longer with improvements in care and treatment, the number of elderly RA patients who may died of complication by cerebrovascular events may gradually increase.